by John Conrad | May 28, 2024 | Member News
MAIA Biotechnology, a cutting-edge biopharmaceutical company, is pioneering a novel approach to cancer treatment that could revolutionize the field of oncology. Their premier drug candidate, THIO, is a first-in-class telomere-targeting agent designed to selectively...
by John Conrad | May 23, 2024 | iBIO News
Whether you’re heading to the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 – June 4, or the BIO International Convention in San Diego from June 3 – 6, the upcoming weeks will be a whirlwind for startup companies...
